Back to catalogue
№ 053 23 filings · 2021-04-30 → 2026-03-11

BODYCOTE PLC

BOY
Industrial Goods and Services Market cap £1.4bn Overall fit 510 /1000

Quality asset-heavy industrial with genuine operating leverage and a fair-to-modestly-cheap valuation, but AI-receiver exposure is indirect (IGT for datacentre power, HIP for aerospace/additive) rather than direct, capping fit with this strategy.

Fair value range 700p–850p Mid case · £1.3bn
Absolute upside -4.5% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean financials and consistent disclosure with restated segmental view
  • Fortress balance sheet (0.6x net debt/EBITDA) limits downside
  • Forward P/E and EV/EBITDA approaches converge on similar fair value
Limits the call
  • Next 12-24 months depend on pace of A&D/IGT acceleration and Auto/Industrial recovery
  • AI-receiver angle is peripheral (IGT-to-datacentre power, some HIP) rather than core
Methodology

Blended forward P/E (14-16x on 2026E adj EPS) and EV/EBITDA (7-8x mid-cycle)

In one line · bull case

Quality global #1 in thermal processing with strong operating leverage to A&D and IGT (incl. datacentre power) recovery, self-help margin expansion from Optimise, and a fortress balance sheet at a fair price.

In one line · biggest risk

Prolonged Automotive and Industrial weakness combined with further high-margin Oil & Gas contract losses could delay margin recovery and trigger fresh goodwill impairments in NA AGI.

Drivers
AI beneficiary 38 /100
Indirect AI exposure via IGT (datacentre power) and HIP for aerospace/additive manufacturing; not a primary AI value-chain play.
Operating leverage 68 /100
High fixed cost base (labour ~37%, utilities/depreciation), 27% Specialist Tech margins, spare capacity post-Optimise — 10-20% revenue beat could plausibly add ~50% to operating profit.
Earnings vs expectations 45 /100
FY25 came in below mid-2025 consensus (£114m vs £120m); 2024 broadly in line; not a serial beater nor a serial misser.
Growth momentum 45 /100
Revenue declined in 2024 and 2025 but H2 2025 Core organic +3.2%, A&D/IGT accelerating, 2026 organic growth expected; not yet a momentum story but inflecting.
Moat 62 /100
Global #1 in thermal processing, Nadcap and IATF accreditations, scale-driven density advantages, ~50yr customer relationships, but not network-effect or pricing-power dominant.
Earnings quality 65 /100
78% cash conversion in 2025 (lower than historic 90% due to capex), recurring exceptional charges (£21m in 2025) related to Optimise; underlying earnings quality reasonable.
Management quality 65 /100
Disciplined capital allocation: 38-year dividend record, £120m of buybacks since 2024 plus £80m new programme, sensible bolt-on M&A (Spectrum); Optimise execution on track.
Cyclicality 70 /100
Materially cyclical via Automotive, Industrial, Oil & Gas; partially offset by long-cycle A&D and IGT.
Leverage 22 /100
Net debt £105m at just 0.6x EBITDA with £156m liquidity headroom — fortress balance sheet.

BODYCOTE PLC (BOY) — Investment Research Note

Executive summary

Bodycote is the world's largest specialist thermal processing services group, operating 136 sites that heat-treat metal components for Aerospace & Defence, Industrial Gas Turbines (IGT), Automotive, Oil & Gas and other industrial customers. Across 2021–2025 revenue grew from £616m to a peak of £802m in 2023 before contracting to £727m in 2025, with adjusted operating margin sliding from 17.0% in 2024 to 15.7% in 2025 as a mix shift away from high-margin Oil & Gas work, soft Automotive/Industrial demand, and an ongoing portfolio restructuring (the "Optimise" programme) weighed on profit. The single most important point for valuation today is that Core organic revenue inflected positive in H2 2025 (+3.2%), A&D and IGT are accelerating, and ~£15m of run-rate Optimise savings plus a normalising revenue mix should produce strong operating leverage into 2026–2027 — provided you accept that BOY is only a peripheral AI-receiver via IGT-for-datacentres and HIP-for-aerospace.

Fair value estimate

Fair value range: 700p – 850p per share (implied market cap £1,215m – £1,475m)

Methodology: blended forward P/E on adjusted EPS and EV/EBITDA cross-check.

  • 2025 adjusted EPS 44.4p; with Optimise benefits (£4m), Core revenue growth and mix recovery, 2026E adjusted EPS plausibly 47–52p, mid-cycle 53–58p.
  • Apply 14–16x forward P/E (in line with quality industrial services peers with strong balance sheets) → 700p–830p.
  • EV/EBITDA cross-check: adjusted EBITDA £185m (2025), normalising to £200m mid-cycle; at 7–8x EV/EBITDA = EV £1,400m–£1,600m; less net debt of £105m → equity £1,295m–£1,495m, or ~745p–860p per share.
  • Buyback (£80m new programme on ~173.5m shares) provides ~4% EPS tailwind.

Vs. current £1,170.4m market cap (~675p): mid-point fair value ~775p, implied upside ~15%. View: fair to modestly undervalued.

Sector context

  • Sector confirmed: Industrial Goods & Services (Industrials super-sector, asset-heavy services).
  • Quality profile is above typical sector peers: 38-year dividend track record, fortress balance sheet (0.6x net debt/EBITDA), ROCE 14.2%, strong cash conversion. Growth profile (4% CAGR through cycle) is in line with sector; leverage well below typical industrial peers.
  • Listed peers: Hexcel, Wallwork Heat Treatment (private), Aalberts NV (more diversified), parts of IMI plc and Spirax Group for industrial-service comparables; closest standalone listed comp for thermal processing is limited — Bodycote is genuinely the global leader with no listed peer of comparable purity.

Investment thesis

  • Self-help margin recovery underway: Optimise programme delivered £4m savings in 2025 with a further £4m incremental in 2026, targeting ≥£15m run-rate by mid-2027 on ~£10–15m net cash cost. Perform programme adds ~100bps Group margin by 2028. Combined with operational gearing on returning A&D / IGT volumes, this drives margin and EPS expansion even without heroic top-line assumptions 2026-03-11 final results.
  • High-quality long-cycle exposure to A&D and IGT compounding: Aerospace & Defence and IGT are accelerating into 2026 with strong order books — Spectrum acquisition (Jan 2026) deepens US Aerospace footprint; new HIP, S³P and Mexican Auto capacity coming online late 2026/early 2027 provides growth runway. IGT itself benefits from data-centre power demand, giving an indirect AI-receiver kicker 2025-11-18 November Trading Update; 2026-01-16 Spectrum acquisition.
  • Strong balance sheet supports disciplined capital return: net debt £104.8m (0.6x EBITDA), £121.8m RCF headroom, £80m new buyback to complete by end-2027, dividend held at 23p with 38-year unbroken record. Investor gets paid to wait, and the Group has firepower for further bolt-on M&A 2026-03-11 final results.

Key risks

  • Cyclical Automotive & Industrial exposure remains weak: roughly half of Precision Heat Treatment is tied to Auto/Industrial cycles which the company itself describes as "challenging in the near term" — a deeper recession would delay the margin recovery 2026-03-11 final results outlook.
  • High-margin Oil & Gas revenue concentration is exposed: 2025 saw Specialist Technologies margin drop 240bps as Oil & Gas revenue fell ~40% after a sizable UK contract ended; further Middle East upstream weakness or contract losses materially hits Group margin 2026-03-11 final results, ST segment.
  • Restructuring execution and goodwill risk: Optimise programme is mid-flight; £2.1bn cumulative exceptional charges in 2024–2025 (£78m + £21m) reflect site closures and impairments. NA AGI goodwill (~£40m) has thin headroom; any further automotive weakness could trigger fresh impairments (not disclosed but inferred from 2025 sensitivity disclosures) 2026-03-11 final results goodwill note.

Operating leverage

Bodycote runs a high-fixed-cost asset base: 2025 cost lines include £268m employee costs (37% of revenue), £70m utilities (~10%), and £56m+ depreciation. Gross margin of 39% (cost of sales £446m) implies a meaningful variable component (consumables, gases, transport ~£140m), but the labour/utility/depreciation block is largely fixed in the short term. Specialist Technologies runs at 27% adjusted operating margin vs 16% for Precision Heat Treatment; HIP, S³P and Surface Technology businesses are capacity-constrained with significant spare capacity post-Optimise. On a 10–20% revenue beat above current expectations, contribution margin on incremental volumes plausibly drops at ~35–45% to operating profit, which would translate to a ~50% lift in adjusted operating profit at the high end. The 2024→2025 transition demonstrates the reverse leverage clearly: revenue fell 4% but operating profit fell 11%. Inflection points: (1) ST capacity utilisation in Aerospace post-Spectrum + new HIP/S³P sites coming online late 2026, (2) Auto/Industrial cyclical recovery dropping straight onto spare capacity. The medium-term target of >20% Group operating margin (vs 15.7% today) implies ~£40m+ profit uplift on flat revenues — a useful sanity check on the operating leverage 2026-03-11 final results; 2025-07-30 Interim.

Value-trap signals

  • Five-year revenue trajectory has been choppy (peak in 2023, down ~9% to 2025) but each year explained by identifiable end-market issues, not structural decline.
  • Free cash flow conversion fell to 42% in 2025 (from 55% in 2024 and 75% in 2023) due to capex and restructuring spend — worth monitoring but explained by growth investment.
  • 2024 saw £78m exceptional charges including £18m goodwill impairment and £28m ERP write-down; 2025 a further £21m. These are real costs, not just accounting noise, but the underlying business is cash-generative.
  • No customer concentration (no customer >10% of revenue), no related-party concerns, no going-concern issues, no dividend cuts.
  • Conclusion: None of the classic value-trap signals identified.

Earnings vs. expectations

  • FY24 vs FY23: Revenue -5.7%, adj. operating profit modestly up (+1.1%) — guidance had been for "resilient" performance; broadly met expectations.
  • H1 2025: "in line with May trading update; full year outlook unchanged"; vs company-compiled consensus FY25 op profit range £115.7–£123.0m, mean £119.9m.
  • FY25 actual: adjusted operating profit £114.3m — slightly below the £119.9m mean consensus referenced at H1; revenue £727.1m vs implied consensus £718m at May 2025.
  • May 2025 trading update: "FY outlook in line with market expectations" — held; then November update flagged H2 op profit "broadly similar to H2 2024" (£62.2m).
  • Pattern: Bodycote has been broadly meeting or modestly missing in 2024–2025 as Oil & Gas project losses and Auto/Industrial weakness eroded the back half. Not a serial beater, not a serial misser — call it "in line with a slight miss bias" over the past 18 months.

Conviction

Conviction: 3 (moderate)

Anchors: (1) clean, audited financials with consistent disclosure and a clear segmental view post-Optimise restatement; (2) strong balance sheet and stable cash generation make the downside well-bounded; (3) two independent valuation methods (forward P/E and EV/EBITDA) converge on a similar 700–850p range.

Limits: (1) the next 12–24 months of earnings depend materially on the pace of A&D/IGT acceleration and the timing of Auto/Industrial recovery — both forecastable but not certain; (2) the AI-receiver angle is genuinely peripheral (mainly IGT for datacentre power and some HIP additive-manufacturing demand), so the investor profile fit is partial.

Filings consulted · 31

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-03-11Final Results2026-03-11_9468360_final-results.md1.00
  2. 2026-01-16Acquisition OF Spectrum Thermal Processing2026-01-16_9357795_acquisition-of-spectrum-thermal-processing.md0.75
  3. 2025-11-21Completion OF Disposal OF Ten Non Core Sites2025-11-21_9248480_completion-of-disposal-of-ten-non-core-sites.md0.64
  4. 2025-11-18November Trading Update2025-11-18_9240105_november-trading-update.md0.72
  5. 2025-07-30Bodycote Plc 2025 Interim Results2025-07-30_9011576_bodycote-plc-2025-interim-results.md0.77
  6. 2025-05-27Post Agm Trading Update2025-05-27_8897310_post-agm-trading-update.md0.55
  7. 2025-05-21Result OF Agm2025-05-21_8890493_result-of-agm.md0.20
  8. 2025-03-14Full Year Results For Year Ended 31 December2025-03-14_8779279_full-year-results-for-year-ended-31-december.md0.65
  9. 2024-11-19Trading Statement2024-11-19_8558111_trading-statement.md0.55
  10. 2024-07-30Interim Results For The Six Months TO 30 June 20242024-07-30_8337081_interim-results-for-the-six-months-to-30-june-2024.md0.58
  11. 2024-05-30Result OF Agm2024-05-30_8231966_result-of-agm.md0.20
  12. 2024-05-30Agm Trading Update2024-05-30_8230256_agm-trading-update.md0.55
  13. 2024-03-15Full Year Results For Year Ended 31 December 20232024-03-15_8089334_full-year-results-for-year-ended-31-december-2023.md0.45
  14. 2024-01-22Acquisition Update And Share Buyback Programme2024-01-22_7998819_acquisition-update-and-share-buyback-programme.md0.34
  15. 2023-11-22Trading Update2023-11-22_7895705_trading-update.md0.38
  16. 2023-10-09Specialist Tech Acquisitions Amp New Hip Facility2023-10-09_7803716_specialist-tech-acquisitions-amp-new-hip-facility.md0.34
  17. 2023-07-27Interim Results For The Six Months TO 30 June 20232023-07-27_7657764_interim-results-for-the-six-months-to-30-june-2023.md0.41
  18. 2023-05-31Trading Update2023-05-31_7551495_trading-update.md0.38
  19. 2023-05-31Result OF Agm2023-05-31_7552949_result-of-agm.md0.14
  20. 2023-03-17Full Year Results For Year Ended 31 December 20222023-03-17_7475880_full-year-results-for-year-ended-31-december-2022.md0.25
  21. 2022-11-18Trading Update2022-11-18_7414760_trading-update.md0.21
  22. 2022-07-29Interim Results For The Six Months TO 30 June 20222022-07-29_6916555_interim-results-for-the-six-months-to-30-june-2022.md0.23
  23. 2022-05-25Trading Update2022-05-25_6977294_trading-update.md0.21
  24. 2022-05-25Result OF Agm2022-05-25_7026269_result-of-agm.md0.07
  25. 2022-04-04Final Dividend Payment Date2022-04-04_7174135_final-dividend-payment-date.md0.07
  26. 2022-03-14Full Year Results For Year Ended 31 December 20212022-03-14_6896754_full-year-results-for-year-ended-31-december-2021.md0.25
  27. 2021-11-23Trading Update2021-11-23_6837504_trading-update.md0.21
  28. 2021-07-29Interim Results For The Six Months TO 30 June 20212021-07-29_6783613_interim-results-for-the-six-months-to-30-june-2021.md0.23
  29. 2021-05-27Trading Update2021-05-27_6516276_trading-update.md0.09
  30. 2021-05-27Result OF Agm2021-05-27_6517666_result-of-agm.md0.03
  31. 2021-04-30Replacement Notice OF Agm2021-04-30_6670456_replacement-notice-of-agm.md0.03

This research note was authored by a large language model after reading 23 regulatory filings published between 2021-04-30 and 2026-03-11. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.